Skip to main content

Table 2 TILs distribution according to tumor subtype and clinical characteristics

From: Immune characterization of breast cancer metastases: prognostic implications

  TILs %, median (Q1 – Q3): all patients 5 (2–10)
Overall p value TN p value HER2+ p value
Tumor phenotype
 TN 5 (2–10)    
 HER2+ 5 (2–11) 0.855
Age at BC diagnosis
  ≤ 50 years 3 (2–8) 0.002 3 (2–10) 0.037 4 (2–8) 0.010
  > 50 years 8 (5–15) 7 (4–11) 9 (5–18)
HR status
 Negative 9 (5–15) 0.029
 Positive 4 (2–8)
Organ/site of biopsy
Liver 5 (2–8) 0.277 5 (5–11) 0.936 5 (2–8) 0.119
Skin 3(2–10) 3 (2–10) 4 (2–10)
Lung 9 (5–18) 8 (3–10) 18 (6–19)
CNS 6 (3–11) 4 (3–38) 11 (5–11)
Other 5 (2–8) 5 (2–19) 5 (2–8)
Pre-biopsy systemic treatment for MBC
 No 5 (3–11) 0.563 5 (3–10) 0.104 4 (2–13) 0.652
 Yes 5 (2–8) 2 (2–5) 6 (5–9)
  1. Abbreviations: TILs tumor-infiltrating lymphocytes, Q1 first quartile, Q3 third quartile, p p value, significant values in bold, TN triple negative, HER2 human epidermal growth factor receptor-2, BC breast cancer, HR hormone receptor, CNS central nervous system, MBC metastatic breast cancer